Matches in SemOpenAlex for { <https://semopenalex.org/work/W2491297043> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2491297043 abstract "One of the Food and Drug Administration’s (FDA) key mandates is to ensure that drug products are safe and effective, and for excipients, the pharmacologically inert ingredients that constitute most of a drug product, a key safety issue is purity. Unfortunately, there are many well-known examples of patient harm that resulted from excipient impurities. For example, in 1996, the CDC reported that 86 children in Haiti died when given a pediatric acetaminophen syrup containing glycerin contaminated with diethylene glycol (1). This glycerin was apparently manufactured in China (China would not let investigators verify this) and shipped through Europe to Haiti, using a supply chain with several participants. The product was shipped with no traceability and with insufficient controls and documentation needed to avoid or even reduce manipulation and alteration of the material. This tragic example illustrates what can happen when the components of a drug product are improperly handled. The fact that this incident happened in Haiti may lead some manufacturers to say it could not happen here in the United States, but as the excipient business becomes more global and more of a commodity business, increased care will be required to ensure that similar incidents do not happen. Section 501 [21 U.S.C. 351] of the Federal Food Drug and Cosmetic Act (FFDCA) act describes the conditions under which a drug or device may be deemed to be adulterated. One of the requirements of the act is that the drug be manufactured under current GoodManufacturing Practices (cGMP). Pursuant to this provision of the federal FFDCA act, the regulations that follow describe the intent of this provision, which is to ensure the finished drug product meets the expected safety, identity, strength, purity, and quality characteristics that it purports or is represented to possess. For finished drug products, cGMP under 21 CFR, Parts 210 and 211, refers to the finished drug products. Section 501(a)(2)(B) of the FFDCA requires that all" @default.
- W2491297043 created "2016-08-23" @default.
- W2491297043 creator A5016696250 @default.
- W2491297043 creator A5075255783 @default.
- W2491297043 date "2006-07-28" @default.
- W2491297043 modified "2023-10-12" @default.
- W2491297043 title "Excipient Quality Assurance: Handling, Sampling, and Regulatory Issues" @default.
- W2491297043 cites W1566319445 @default.
- W2491297043 cites W1964220924 @default.
- W2491297043 cites W1974622948 @default.
- W2491297043 cites W1978661004 @default.
- W2491297043 cites W2000868500 @default.
- W2491297043 cites W2012554344 @default.
- W2491297043 cites W2027883279 @default.
- W2491297043 cites W2065847076 @default.
- W2491297043 doi "https://doi.org/10.1201/9781420004137-25" @default.
- W2491297043 hasPublicationYear "2006" @default.
- W2491297043 type Work @default.
- W2491297043 sameAs 2491297043 @default.
- W2491297043 citedByCount "0" @default.
- W2491297043 crossrefType "book-chapter" @default.
- W2491297043 hasAuthorship W2491297043A5016696250 @default.
- W2491297043 hasAuthorship W2491297043A5075255783 @default.
- W2491297043 hasConcept C111472728 @default.
- W2491297043 hasConcept C112930515 @default.
- W2491297043 hasConcept C138885662 @default.
- W2491297043 hasConcept C144133560 @default.
- W2491297043 hasConcept C17744445 @default.
- W2491297043 hasConcept C199360897 @default.
- W2491297043 hasConcept C199539241 @default.
- W2491297043 hasConcept C2524010 @default.
- W2491297043 hasConcept C2777239854 @default.
- W2491297043 hasConcept C2777363581 @default.
- W2491297043 hasConcept C2779530757 @default.
- W2491297043 hasConcept C2780035454 @default.
- W2491297043 hasConcept C33923547 @default.
- W2491297043 hasConcept C41008148 @default.
- W2491297043 hasConcept C56666940 @default.
- W2491297043 hasConcept C71924100 @default.
- W2491297043 hasConcept C90673727 @default.
- W2491297043 hasConcept C98274493 @default.
- W2491297043 hasConceptScore W2491297043C111472728 @default.
- W2491297043 hasConceptScore W2491297043C112930515 @default.
- W2491297043 hasConceptScore W2491297043C138885662 @default.
- W2491297043 hasConceptScore W2491297043C144133560 @default.
- W2491297043 hasConceptScore W2491297043C17744445 @default.
- W2491297043 hasConceptScore W2491297043C199360897 @default.
- W2491297043 hasConceptScore W2491297043C199539241 @default.
- W2491297043 hasConceptScore W2491297043C2524010 @default.
- W2491297043 hasConceptScore W2491297043C2777239854 @default.
- W2491297043 hasConceptScore W2491297043C2777363581 @default.
- W2491297043 hasConceptScore W2491297043C2779530757 @default.
- W2491297043 hasConceptScore W2491297043C2780035454 @default.
- W2491297043 hasConceptScore W2491297043C33923547 @default.
- W2491297043 hasConceptScore W2491297043C41008148 @default.
- W2491297043 hasConceptScore W2491297043C56666940 @default.
- W2491297043 hasConceptScore W2491297043C71924100 @default.
- W2491297043 hasConceptScore W2491297043C90673727 @default.
- W2491297043 hasConceptScore W2491297043C98274493 @default.
- W2491297043 hasLocation W24912970431 @default.
- W2491297043 hasOpenAccess W2491297043 @default.
- W2491297043 hasPrimaryLocation W24912970431 @default.
- W2491297043 hasRelatedWork W1485056095 @default.
- W2491297043 hasRelatedWork W2188394380 @default.
- W2491297043 hasRelatedWork W2230335000 @default.
- W2491297043 hasRelatedWork W2346007679 @default.
- W2491297043 hasRelatedWork W2589294521 @default.
- W2491297043 hasRelatedWork W3110265680 @default.
- W2491297043 hasRelatedWork W3167063770 @default.
- W2491297043 hasRelatedWork W3179826156 @default.
- W2491297043 hasRelatedWork W150552420 @default.
- W2491297043 hasRelatedWork W2157307941 @default.
- W2491297043 isParatext "false" @default.
- W2491297043 isRetracted "false" @default.
- W2491297043 magId "2491297043" @default.
- W2491297043 workType "book-chapter" @default.